~" The authors reviewed 229 consecutive patients treated intramurally by resection of solitary cerebral metastasis. Patients were classified into four groups on the basis of whether a gross total resection or subtotal resection was performed and whether systemic disease was present or absent at the time of craniotomy. Group 1 had gross total resection and no systemic disease; Group 2 had subtotal resection and no systemic disease; Group 3 had subtotal resection and systemic disease; and Group 4 had gross total resection and systemic disease. All four groups were further subdivided into Subgroup A (adjuvant whole-brain radiation therapy) or Subgroup B (no adjuvant radiation). Data were collected regarding multiple patient and tumor variables for multivariate analysis. Survival data for the 46 patients in Group IA (median 1.3 years, 2-year survival rate 41%, 5-year survival rate 21%) were markedly better than those for the 75 in Group IB (median 0.7 year, 2-year survival rate 19%, 5-year survival rate 4%). The 20 patients in Group 2A also had superior survival data (median 1.1 years, 2-year survival rate 30%, 3-year survival rate 313%) when compared with the eight patients in Group 2B (median 3 months, 1-year survival rate 0%). However, the 16 and 22 patients in Groups 3A and 4A, respectively, had no discernible differences compared to the seven and 35 patients in their Group 3B and 4B counterparts. Multivariate analyses were performed to assess the association of survival with multiple patient, disease, and treatment variables. Poor neurological status and systemic disease were significantly associated with inferior survival, while longer (> 36 months) intervals between primary diagnosis and craniotomy were significantly associated with improved survival. After adjusting for the effects of other patient, disease, and treatment characteristics, adjuvant whole-brain radiotherapy was significantly associated with improved survival times. These data support the continued use of craniotomy followed by adjuvant wholebrain radiation therapy for treatment of solitary brain metastasis. However, this aggressive therapy appears relatively contraindicated in the face of either systemic disease or substantial neurological deficit. KEY WORDS 9 brain neoplasm 9 metastasis eraniotomy radiation therapy 9 prognosis I NTRACEREBRAL metastatic disease is an extremely common and devastating problem. Parenchymal brain metastases are reported in approximately 10 % to 15 % of cancer patients both in autopsy series 32' 34 and in clinical reports. 49 This results in 100,000 to 150,000 new cases of intracerebral metastatic disease occurring each year in the United States. Furthermore, the incidence of brain metastasis appears to be increasing as a result of improved systemic chemotherapy, improved locoregional treatment modalities, and the increasing incidence of lung cancer and melanoma.32'33 The majority of cerebral metastases are managed by palliative radiotherapy. Radiotherapy has been demonstrated in randomized ~z'22 and nonrandomized 24"27' -~7' 47 studies to improve neurological function in the majority of cases. Unfortunately, regardless of the timedose-fraction scheme used, median survival time remains a dismal 3 to 6 months. J2.22.27.47 This therapeutic impotence has provided impetus for exploration of a variety of innovative treatments including brachytherapy, 6'7~35 neutron therapy, 25 radiation-chemotherapy combinations, ~'t~'26 and complex external beam therapies such as gamma knife 2~ or linear accelerator radiosurgery. J s.4t The multitude of these investigations bears testimony to the frustration experienced by oncologists who deal with this problem and the need for careful evaluation of aggressive treatment philosophies in favorable subsets of afflicted patients.
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Occasionally, surgical excision of a solitary cerebral metastasis is considered. Approximately 30% to 40% of metastases to the brain are clinically solitary, '-''4 and 3% to 5% of patients with brain metastasis have the brain as their sole site of metastatic disease. 32 Enthusiasm for surgical removal of solitary brain metastases is variable, with some ~ ~13' 24"42' 4348 strongly recommending this approach in patients with surgically accessible lesions who are otherwise clinically free of disease. Others ~6~~ are more reticent about recommending such a procedure. The Radiation Therapy Oncology Group "; reported no improvement in survival, palliation, or differences in cause of death when comparing those who underwent a surgical procedure with those treated with radiation alone. The Vanderbilt group also demonstrated similar outcome in patients treated with surgery plus irradiation versus those treated with irradiation alone. :7 Some of the disagreement regarding the role of surgical removal of brain metastasis may be a result of the differing selection criteria employed for this procedure in various reports. Therefore, we have reviewed our large intramural experience in 229 consecutive patients selected for a surgical approach to brain metastasis in an effort to describe the outcome of a variety of clinical presentations when this approach is employed. Moreover, there is some debate regarding the role of postoperative radiation therapy following resection of a solitary brain metastasis. ~t-3' We have also reviewed our experience in an effort to describe the behavior of patients who underwent adjuvant radiotherapy compared to those who were simply observed following metastatectomy. We believe this review defines clinically relevant subsets of patients with potentially resectable cerebral metastatic disease, clarifies important prognostic variables, and evaluates the efficacy of postoperative radiotherapy.
Clinical Material and Methods

Patient Population
The study population includes all patients who underwent attempted removal of cerebral metastatic lesions at the Mayo Clinic between January 1, 1972, and December 1, 1982. Data were collected retrospectively regarding various patient and disease factors, including age at diagnosis of primary tumor, age at craniotomy, sex, primary tumor site, tumor histology and grade, and interval from date of primary diagnosis (if the primary, site was known) to craniotomy. Patients were evaluated by neurologists prior to craniotomy and their medical histories and neurological examinations were recorded on a standard form.-" Patients were classified on the basis of this examination into one of three functional neurological groups: Class I patients were fully active and had either no or only mild neurological deficits; Class II included patients with moderate neurological deficits who were ambulatory; and Class III consisted of patients who exhibited severe deficits and were not ambulatory. Cerebral lesions were characterized by side (right, left, or midline), site (frontal, temporal, parietal, occipital, cerebellar, or multilobed), and size.
For the present study, patients were divided into four clinical groups based upon two clinically and prognostically relevant parameters: the presence or absence of documented noncerebral systemic disease at the time of craniotomy and the ability of the neurosurgeon to achieve a gross total resection of the tumor. Group 1 patients had gross total resection and no systemic disease; Group 2 patients had subtotal resection but no systemic disease; Group 3 patients had both subtotal resection and systemic disease; and Group 4 patients had a gross total resection but also had systemic disease at the time of craniotomy. All four groups were further subdivided into those who received postcraniotorny adj uvant whole-brain radiation therapy (Subgroup A) and those who received no postoperative adjuvant wholebrain radiation therapy (Subgroup B). Radiotherapy was characterized by total dose, fraction size, and continuous versus split-course administration.
Statistical Analysis
Surgical curves from the time of craniotomy were estimated by using the Kaplan-Meier 21 method, and survival differences among the groups were assessed using the log rank test. In an attempt to separate the effect of radiotherapy from the effects of patient and disease factors that might have subtly influenced the decision to administer radiotherapy and the choice of dose levels, we elected to analyze the data using covariate analysis techniques (regression tree models 4 and Cox proportional hazards models 7) to assess the association of survival with multiple patient, disease, and treatment characteristics. To assess treatment effects due to radiotherapy, we defined two dichotomous (yes/ no) variables: adjuvant radiotherapy was scored as 1 if it was given, or 0 otherwise; and high-dose radiation therapy (39 Gy or more) was scored 1 if administered, or 0 otherwise. The third treatment variable we defined was gross total resection, assigning a score of 1 if performed, or 0 otherwise. To assess patient factors that might be prognostic (age, sex, and neurological status at craniotomy), we defined three variables: "old" was classified 1 if the patient's age was 50 years or over, or 0 otherwise; "male" was scored 1, and female 0; and presence of a moderate or severe neurological deficit was assigned a score of 1, or 0 otherwise. To quantify potential prognostic factors among disease characteristics, we defined 13 dichotomous variables: three to characterize the site of the primary lesion (lung, visceral, or unknown); two to partition the interval from diagnosis of primary tumor to craniotomy into three parts (long interval (> 36 months) or short interval (no diagnosis before surgery)); two to characterize the extent of disease at time of craniotomy (systemic or controlled disease); four to characterize the location of central nervous system (CNS) disease (left side, frontal lobe, Adjuvant radiation for brain melastases cerebellum, or multilobe); and two to partition the size of the CNS lesion into three maximum diameter classes (small (_< 2 cm) or large (> 4 cm)).
Initially, we performed forward slepwise modeling procedures on the total group of 229 patients to generate the 19 Cox single-variable proportional hazards models (each containing exactly one of the 19 covartares defined above) followed by the series of multivariate Cox models in which covariates are successively added in decreasing order of the strength of their association with length of survival. We also performed backward stepwise modeling procedures in which covariates are successively removed from the model in increasing order of strength of association with survival time. The single-variable models measure the association of survival with each of the covariates individually, while the multivariate models measure the strength of association of survival period with each of the covariates after adjustment for the effects of the other variables in the model. The backward stepwise procedure can often reveal cases in which a pair of variables (for instance, height and weight) measures an underlying variable that was not directly observed in the dataset (for instance, obesity). We also performed regression tree analysis to try.' to identify any patient subsets having different sets of prognostic variables.
Results
A total of 229 craniotomies were performed with the goal of resection of all metastatic cerebral disease. Of these, 121 patients were rendered completely clinically disease-free after craniotomy (Group 1). Twenty-eight patients with no evidence of systemic disease at the time of craniotomy underwent a subtotal resection (Group 2). Twenty-three patients with clinically manifest systemic disease at the time of eraniotomy underwent subtotal resection of their cerebral metastatic disease (Group 3). Finally, 57 patients with extracerebral disease present at the time of craniotomy underwent a gross total resection of all cerebral metastatic disease (Group 4).
The characteristics of both the total cohort of 229 patients and each of the Groups 1 through 4 are shown in Table 1 . In general, the patient characteristics were relatively favorable. The median age at craniotomy was not elderly, and there was often a reasonably long median interval from the time of the primary diagnosis to the date of craniotomy. The overwhelming majority had at most a moderate degree of neurological deficit at the time of craniotomy. Although the lung was clearly the most common primary tumor site, other primary sites with potentially more favorable natural histories had substantial representation. There was some tendency for the CNS lesion to be small (_< 4 cm), to arise in the nondominant hemisphere, and to be located in sites potentially more amenable to surgical extirpation, By definition, all of these patients had only a single lesion, which might also be expected to confer upon this cohort a more favorable outcome. (14) 1 (4) 8 (14) 25 (11 ) unknown 25 (21) 7(25) 2(9) 1 (2) 35(15) renal 9(7) 0(0) 0(0) 4(7) 13(6) colorectal 13(11) 1{4) 3 (13) 7 (12) 24 (10) other 8 (7) 3 (11) 3(t3) 6(11) 20(9) CNS site temporal 7(6) 3 (11) 1 (4) 1 (2) 12 (5) frontal 23 (19) 4 (14) 3 (13) 9 (16) 39 (17) parietal 15 (12) 4 (14) 4 (17) 8 (14) 31(14) occipital 9 (7) 3(1 l) 1(4) 2(4) 15 (7) cerebellum 34 (28) 4 (14) 5 (22) 20 (35) There were several interesting similarities and differences in patient characteristics among the four groups. The subsets were quite similar in the distribution of age, sex, interval from diagnosis to craniotomy, primary diagnosis, and location of CNS disease. However, there were significant differences (p < 0.02) in the distributions of neurological status and size of CNS lesions. As one would expect clinically, there were also significant differences (p < 0.01 ) in the percentage of patients who received further therapy (radiation and/or chemotherapy) following craniotomy.
Of the total 229 patients, 209 were followed until death. For the 20 patients still alive at the time of analysis, the median time from craniotomy to last followup contact was 3.0 years (range 1.3 to 12.4 years).
Survival Curves
The survival curves calculated from the date of craniotomy of Groups 1 to 4 are shown in Fig. I . Group I patients (gross total resection of the cerebral metastasis and no systemic disease) had the most favorable outcome. The median survival time was approximately 11.7 months with 2-year, 3-year, and 5-year survival rates of 39%, 19%, and 10%, respectively. Fourteen patients were still living at last follow-up contact, with a median follow-up interval of approximately 3.4 years (range 1.9 to 12.4 years). Group 2 patients (subtotal resection of cerebral metastasis and no systemic disease) had a much poorer outcome with a median survival period of approximately 7.7 months. The 1-year, 2-year, 3-year, and 5-year survival rates were 43%, 21%, 21%, and 0%, respectively. Three patients were alive at the time of last follow-up contact at periods ranging from 2.0 to 3.2 years. The survival rate of Group 3 patients (subtotal resection of cerebral metastasis and systemic disease present at the time of craniotomy) was dismal. The median survival time was approximately 5.3 months. The 1-year, 2-year, and 3-year survival rates were 35%, 17%, and 13%, respectively. No patient was alive at last follow-up contact and none lived beyond 3.3 years.
Group 4 patients (gross total resection of cerebral metastasis and systemic disease present at the time of craniotomy) likewise has a poor outcome. Their median survival time was approximately 6.8 months. The 1-year, 2-year, and 3-year survival rates were 28%, 12%, and 6%, respectively. Three patients were alive at the variables. RT = radiation therapy; GI = gastrointestinal; GU = genitourinary; CNS = central nervous system. time of last follow-up contact at periods ranging from 1.3 to 2.1 years and no patient survived more than 3.6 years. The survival distributions of the four groups as shown in Fig. 1 are significantly different (two-tailed log rank, p < 0.001).
Survival Correlated With Whole-Brain Radiation Therapy
Each group was subdivided into Subgroup A (postcraniotomy adjuvant radiotherapy) and Subgroup B (no adjuvant irradiation or treatment unknown). There was substantial variation in the total dose, fraction size, and split-versus continuous-course administration of the radiotherapy given to the 104 patients who received radiation therapy. The median total dose was 36 Gy (range 10 to 65 Gy) with a median fraction size of 3 Gy (range 1.5 to 5.0 Gy) and a median fraction number of 10 (range 5 to 36).
The survival curves for Groups I A and 1B are shown in Fig. 2 left. The 46 patients who received adjuvant radiation had significantly better survival data (twotailed log rank, p < 0.001) than the 75 patients who did not. The median survival period of Group 1A was 1. 3-year, and 5-year survival rates in Group 1A were 70%, 41%, 30% and 21%, respectively. Ten patients are still living with a median follow-up interval of about 3.2 years (range 1.9 to 6.7 years). In contrast, Group 1B had l-year, 2-year, 3-year, and 5-year survival rates of 34%, 19 %, 12%, and 4%, respectively. Three patients were still living at the time of last follow-up contact, 2.5 to 12.4 years following craniotomy.
The survival distributions of Group 2A versus Group 2B are shown in Fig. 2 right. The 20 patients who received adjuvant radiotherapy had much better survival times following craniotomy than did the eight patients without adjuvant therapy (two-tailed log rank, p < 0.001). The median survival period of Group 2A was 1.1 years, with 1-year, 2-year, and 3-year survival rates of 60%, 30%, and 30%, respectively. There were no 5-year survivors, but three patients were still alive at 2.0 to 3.2 years. Group 2B patients, however, had a median survival period of only 3 months; there were no &month survivors. The apparent survival superiority cannot be attributed to treatment differences alone, since Group 2A contained patients with better neurological status at craniotomy (the distributions of neurological status Classes I to III were 30%, 50%, and 20%, respectively, for Group 2A, and 12.5%, 50%, and 35.5% for Group 2B).
The survival curves for Group 3A versus Group 3B and Group 4A versus Group 4B are shown in Fig. 3 . There were no significant differences among subgroups in either Group 3 or Group 4. Median, 1-year, 2-year, and 3-year survival values were quite similar in each subgroup comparison. There were no 5-year survivors in any of the four subgroups.
Multivariate Analysis to Identify Prognostic Variables
Since adjuvant radiotherapy was not administered within the context of a prospectively randomized and stratified trial, there was concern that the group of patients who did not receive adjuvant radiotherapy included those who died early or otherwise deteriorated rapidly following craniotomy. In effect, this would remove the weakest ones from the radiotherapy group (Subgroup A) and place the early deaths in the nonradiotherapy group (Subgroup B). Unfortunately, there was some evidence that such a bias might exist: at the time of the first death in Subgroup B (at 21 days postcraniotomy), 33% of the patients in Subgroup A had not yet begun adjuvant radiotherapy; and when 20% of Subgroup B patients had died (106 days postcraniotomy), there were still two patients in Subgroup A who had not yet begun adjuvant irradiation.
The multivariate analyses using Cox models confirmed the prognostic importance of several patient and disease variables in the entire group of 229 patients. The results shown in Table 2 reflect the strength of the association between the variable and survival data in the full model containing all 19 variables. It is apparent that location of the metastatic lesion in multiple lobes or in the cerebellum, poor neurological status at the time of craniotomy, male gender, and the presence of systemic disease are associated with poor prognosis, as indicated by the positive D? values. On the other hand, patients receiving gross total resections, those with long disease-free intervals (> 36 months) prior to craniotomy, and lung, genitourinary, or gastrointestinal primary tumors, had a better survival rate than expected, as indicated by the negative 5 values. After adjusting for the effects of all other patient and tumor characteristics analyzed, adjuvant radiation therapy was statistically associated with improved survival times (p < 0.001).
Since the multivariate Cox models suggested the presence of interactions (positive and/or negative synergisms) among the 19 variables, regression tree analysis was performed. This analysis identified two patient subsets based on neurological deficit at craniotomy who had somewhat different sets of prognostic variables. For the 80 patients with minimal neurological deficit, the variables most strongly associated with length of survival were systemic disease and a long interval between diagnosis and craniotomy, whereas for the 149 patients with moderate-to-severe neurological deficit at craniotomy, the variables most strongly associated with survival times were adjuvant radiation therapy, gross total resection of the metastatic cerebral lesion, controlled primary disease, and a primary site in the lung.
Subsequent Cox modeling performed independently on these two patient subsets tended to support the identification of these as major prognostic variables (Table 3 ). For patients with minimal neurological deficit, the hazard function (the risk of dying at each time point among the patients still alive at that time) was estimated to increase with the presence of systemic disease and to decrease with adjuvant radiotherapy, visceral primary tumors, and a long interval between diagnosis and craniotomy. For those with moderate-tosevere neurological deficit, the hazard function was estimated to increase if the lesion was located in the cerebellum or in multiple lobes, and to decrease if the patient received adjuvant whole-brain radiotherapy or gross total resection of the metastatic cerebral lesion, or had a long interval between diagnosis and craniotomy. For both patient groups, adjuvant radiotherapy was strongly associated with an increased period of survival even after adjustment for the effects of the other prognostic factors.
In view of the results of the various multivariate analyses, we examined the survival curves for the four subsets of patients defined by the pair of variables: presence of systemic disease and neurological deficit (Fig. 4) . It can be seen that: 1) the survival distribution for the 61 patients with no systemic disease and minimal neurological deficit at craniotomy is superior to that of the 88 patients with no systemic disease but moderate-to-severe deficit at craniotomy; and 2) the survival curve for the latter group is almost indistinguishable from the curves of those with systemic disease at craniotomy. The median survival period was 91 weeks for the 61 patients with neither systemic disease nor substantial neurological deficit, 35 weeks for the subsets of patients classified by neurological status at craniotomy, Six variables that gave no evidence &association with survival in any patient subset have been omitted from these models. Group sizes are 80 patients with minimal deficit; 149 patients with moderate-to-severe deficit. RT = radiation therapy; CNS = central nervous system. 107 patients with either systemic disease or substantial neurological deficit but not both, and 26 weeks for the 61 patients with both systemic disease and substantial neurological deficit. Estimated 5-year survival rates were 0% for those with systemic disease, 5% for those with substantial neurological deficit only, and 13% for those with neither systemic disease nor substantial neurological deficit.
Discussion
This study must be cautiously interpreted in light of its retrospective nature. It was not a prospectively randomized investigation of the role of either surgery or adjuvant whole-brain radiotherapy. There is evidence to suggest the existence of treatment selection bias in the application of radiotherapy to the patients in this cohort, and patient selection bias is evident in the patient characteristics shown in Table 1 . These patients were relatively young at the time of craniotomy, had a reasonably long interval from the time of primary tumor diagnosis to the date of craniotomy, and did not have severe neurological deficit at the time of their cerebral resection. Lesions were predominantly small (~ 4 cm), arose in the nondominant hemisphere, and were located in surgically accessible sites.
Although our cohort of patients is admittedly a highly selected one, it is appropriate to use some clinical selectivity when considering such an aggressive procedure as a cerebral resection for intracranial metastatic tumor. Moreover, the large number of patients, the long-term follow-up studies, and the variety of clinical presentations make analysis of our material worthwhile. Indeed, the heterogeneity of outcome among these already highly selected patients demonstrates subsets that survive so poorly that the use of this procedure should probably be abandoned, based upon our data.
Systemic Disease
The survival period of patients in Groups 3 and 4 was extremely poor. Both groups had systemic disease at the time of craniotomy; their median survival time ranged from 5 to 7 months, and their l-year and 3-year survival rates were only 28% to 35% and 6% to 13%, respectively. There were no survivors beyond 3.6 years in either group. The extremely poor outcome of these groups of patients with systemic disease present at the time of craniotomy is not discernibly different from series utilizing radiation therapy alone. :7"3747 This leads us to suggest that patients with systemic disease present at the time of the diagnosis of cerebral metastatic disease should rarely, if ever, be managed by craniotomy. Although our data do not specifically address this issue, others have suggested the potential benefit from craniotomy in this setting if the primary tumor is highly sensitive to chemotherapy. Examples of tumors in this category include testicular carcinoma ~ and gestational trophoblastic disease.~~~ Theoretically, one might also consider utilizing craniotomy in systemic tumors that are low grade and have been clinically documented to be indolent in their growth.
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The outcome of patients without systemic disease at the time of craniotomy seems markedly better than one would expect from results of previous series utilizing radiation therapy alone. Certainly, one would expect systemic disease to be associated with substantially inferior survival times, as has been demonstrated in multiple previous neurosurgical series ~424"3742"43 and in most ~ but not all/3 radiotherapy series. The fact that Group 1 patients had a median survival period of almost 1 year and an apparent cure rate of 10%, while those with neither systemic disease nor substantial neurological deficit had a 21-month median survival period and an apparent cure rate of 13% seems markedly better than one would expect from radiotherapy alone, even in this highly selected group of patients. Mandell and colleagues z4 reported a marked survival advantage to patients with a single brain metastasis from nonsmall-cell lung carcinoma if they were treated with surgery plus adjuvant whole-brain radiotherapy (median survival period 16 months) versus those treated with whole-brain irradiation alone (median survival period 4 months). Similarly, Patchell, etal., 3~ reported improved survival times, diminished local recurrence rates, and fewer neurologically related deaths in patients with single brain metastases from nonsmall-cell lung cancer when treated with surgical resection plus radiation versus those treated with radiotherapy only. Furthermore, a prospectively randomized study performed by Patchell and colleagues 3~ at the University of Kentucky Medical Center, randomly assigned 48 patients with single brain metastases to receive either surgical removal followed by radiotherapy or biopsy alone followed by radiotherapy. Recurrence at the site of original metastases (20% vs. 52%, p < 0.05), overall survival period (median 40 vs. 15 weeks, p < 0.05), and time of functional independence (median 38 vs. 8 weeks, p < 0.05) were all significantly improved by surgery followed by radiation therapy versus radiotherapy only. 3~ These consistently reported, reasonably favorable survival results and the apparent ability of this modality to produce cure in a small but significant minority of patients both in our own and in other series 5"14'28'36 '45 provide compelling support for continuing to recommend its use in highly selected groups of patients.
It is not surprising that local control of metastatic disease in the brain is improved with surgery, with or without adjuvant radiotherapy when compared with whole-brain irradiation alone, as has been suggested in multiple series, t~'24'3~ Tumors that are 2 cm or larger would be extremely difficult to sterilize with external beam radiotherapy alone in view of the limitation of normal brain tolerance to radiation. Additionally, data from positron emission tomography suggest that oxygen utilization and blood flow are decreased from the effects of brain metastasis even in the contralateral hemisphere. These decreases in oxygen utilization and blood flow are reversed by resection of brain metastasis and the resultant decrease in intracranial pressure? This finding suggests that oxygenation of microscopic tumor tissue outside the tumor bed, which is clinically undetectable, may be improved by cranial resection. The improved oxygenation of these microscopic metastases may increase their sensitivity to radiation.
Adjuvant Radiotherapy
The role of postoperative adjuvant radiotherapy is difficult to assess from these data. There is troubling evidence that, due to the inevitable inadequacies of retrospective data collection, the adjuvant whole-brain irradiation group failed to include these patients who died or otherwise deteriorated before the radiotherapy originally intended for them could be administered. If such a data-collection bias exists, the true benefit of adjuvant radiotherapy is being inflated to an immeasurable extent by the placement of the earliest treatment failures in the surgery-alone subgroups and the relatively robust candidates (those who survived long enough to begin irradiation) in the adjuvant radiotherapy subgroups. On the other hand, the multivariate analyses provide strong evidence that radiotherapy has a beneficial association with period of survival even after adjustment for the effects of many other potentially important prognostic factors. This strong association of adjuvant whole-brain radiotherapy with improved survival was consistent throughout all of the multivariate analyses performed on the entire cohort of 229 patients. Additionally, when multivariate Cox model analysis was performed on the two major subsets of patients defined by regression tree analysis (those with or without moderate-to-severe neurological deficit), adjuvant radiotherapy was consistently associated with improved survival times after adjustment for the effects of all other potential prognostic factors. Therefore, we continue to advocate adjuvant whole-brain radiotherapy in view of both its strong association with improved periods of survival and the well-documented substantial brain relapse rate following surgical resection alone, which is apparently substantially diminished by adjuvant radiotherapy.
Others have confirmed an extremely low rate of brain tumor recurrence (ranging from 8% to 12%) when whole-brain irradiation follows resection of cerebral metastatic disease? 6' 42 DeAngelis and others 9 reported recurrence following resection in 46% of cases without adjuvant radiation therapy versus only 22% of those with adjuvant radiotherapy, a difference that was statistically significant. Radiation therapy also produced an improved survival period, which was not statistically significant in their series. They queried the potential value of higher-dose lower-fraction-size radiation. We have previously reported 85 Group 1 patients who were followed at the Mayo Clinic. 39 An 85% brain tumor recurrence rate following surgical resection alone versus a 21% rate in those who received adjuvant radiotherapy was observed. Therefore, there seems little doubt that surgery alone is associated with a substantial postoperative brain tumor recurrence problem. This recurrence relates not only to tumor seeding of the wound or even of the craniotomy incision site, 36 but also involves relapses in other sites in the brain. Sundaresan, et al., 44 reported that fully one-third of cranial reoperations following initial resection of a solitary brain metastasis were not in the local tumor bed. Certainly, it is well known that gadolinium-contrast magnetic resonance imaging or high-resolution contrast computerized tomography will reveal multiple cerebral metastases in a substantial number of patients who, without these studies, would carry the diagnosis of a single brain metastasis.
Conclusions
The multivariate analyses of prognostic variables presented here confirm and extend observations made by others. A long interval from the diagnosis of primary tumor to the time of craniotomy and good neurological function preoperatively has been previously reported to be a favorable prognostic variable] TM Interestingly, a primary lung carcinoma is quite consistent with a favorable outcome both in our series and in those of others.5,~4.31,36,45 We also found gastrointestinal and genitourinary tract primary sites to have a favorable association with survival time. Patients with male gender, cerebellar lesions, and lesions involving more than one lobe had poorer outcomes.
This series of patients with solitary cerebral metastasis suggests that systemic disease or substantial neurological deficit is a strong relative contraindication to surgical intervention. Although we have discussed some possible exceptions to this principle, they are uncommon. Patients who manifest long disease-free intervals between the diagnosis of the primary lesion and the cerebral metastasis and have lesions amenable to complete resection are ideal candidates for craniotomy, since the survival period of those receiving subtotal resection was substantially inferior to that in patients whose lesions were completely excised. Following recovery from the craniotomy, we advocate adjuvant radiotherapy. The improved survival periods of patients receiving this adjuvant therapy in our own multivariate analysis as well as in others' experience and the high rate of brain tumor relapse with surgery alone, which is substantially reduced with adjuvant radiation, support this recommendation. Our previous patterns-offailure analysis 39 suggested improved local control when moderate-dose radiotherapy was employed. In this setting of presumed microscopic disease, either within the surgical bed or elsewhere within the brain, a moderate dose of whole-brain radiation therapy may be required to sterilize residual disease. Although moderate-dose radiation therapy (40 to 50 Gy, 1.8 to 2.0 Gy/fraction/ day) subjects patients to an extended course of irradiation, this subgroup is a highly selected subset of patients with cerebral metastasis among whom occasional longterm survival is clearly possible if local brain control can be achieved.
